Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 789 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SCD Clear all
Terminated Not applicable Interventional Results available

A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

NCT04869787
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

NCT00095472
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

NCT00004492
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 25, 2026, 2:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

NCT00639392
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Placebo, Zoledronic Acid
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

NCT00489281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

NCT04395911
View directory record Official record
Conditions
AKI, ARDS, COVID
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 25, 2026, 2:06 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

The BENeFiTS Trial in Beta Thalassemia Intermedia

NCT04432623
View directory record Official record
Conditions
Beta Thalassemia Intermedia, Sickle Cell Disease
Interventions
Benserazide Only Product
Drug
Lead sponsor
Phoenicia BioScience
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • Weston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Hydroxyurea and Transfusion

NCT03644953
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 24 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 25, 2026, 2:06 AM EDT
Completed No phase listed Observational

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)

NCT05604547
View directory record Official record
Conditions
SCD
Interventions
Non-Invasive Infrared Spectroscopy
Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

NCT00186810
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Cyclophosphamide, Horse ATG, Allogeneic stem cell transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 25, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

NCT01000155
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
vorinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 25, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

L-Glutamine Therapy for Sickle Cell Anemia

NCT00586209
View directory record Official record
Conditions
Sickle Cell Anemia, Thalassemia
Interventions
L-Glutamine, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT05477563
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

NCT02105766
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
Interventions
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy, Filgrastim
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

NCT05730205
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Nexplanon 68 MG Drug Implant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Active, not recruiting No phase listed Observational

Neural Circulatory Control and SUDEP Risk.

NCT02813980
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

NCT02447874
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Arginine, Arginine (Loading), Arginine (Continuous)
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

NCT01316796
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Chronic Hemolytic Disorders
Interventions
Sodium Nitrite Cream
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN)

NCT02895841
View directory record Official record
Conditions
Pain
Interventions
SMART app wearable
Other
Lead sponsor
Duke University
Other
Eligibility
8 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 25, 2026, 2:06 AM EDT
Enrolling by invitation Phase 2 Interventional

Open-Label Extension Study to Pioneer Study 6058-SCD-101

NCT07401823
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Pociredir
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Completed No phase listed Observational

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT00011648
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 25, 2026, 2:06 AM EDT